That opens the door for broader access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss. Demand for the injection has soared over the last year ...
Delve into Eli Lilly’s biopharma strategy as it advances its pipeline, wins regulatory milestones, and forges strategic deals ...
Elevance Health Inc. was hit with a proposed class action by a woman who says the insurer wrongly refuses to cover the weight-loss drug Zepbound for patients who need it to treat obstructive sleep ...
Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent ...
Millions of Americans who could benefit from GLP-1 weight-loss drugs are caught in the middle of a battle between drug ...
Medicare Part D beneficiaries experienced a large increase in out-of-pocket spending for GLP-1s in 2025, according to ...
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...
A federal appeals court on Thursday rejected Eli Lilly's appeal of an $183.7 million judgment won by a whistleblowing lawyer ...
Stocktwits on MSN
Why Is Eli Lilly’s Stock Slipping Premarket?
Eli Lilly shares fell 0.6% in premarket trading on Wednesday as safety concerns tied to its rheumatoid arthritis drug ...
The new generation of effective weight loss drugs has generated billions of dollars for industry leaders Eli Lilly (NYSE: LLY ...
Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback